GlassScriptPhysician profile
Sharon A Beckhard
NPI 1649236704
$781.77
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $394 · 2021: $179 · 2022: $45.99 · 2023: $35.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.80 | 2020 | |
| Allergan, INC. | $86.87 | 2020 | |
| Novartis Pharmaceuticals Corporation | $85.08 | 2019-2020 | |
| Biogen, INC. | $71.24 | 2020-2022 | |
| Abbvie INC. | $61.58 | 2021-2023 | Ubrelvy |
| Amneal Pharmaceuticals LLC | $47.58 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $44.89 | 2021 | |
| Tersera Therapeutics LLC | $41.42 | 2019 | |
| Lilly USA, LLC | $39.66 | 2020-2021 | |
| Acorda Therapeutics, INC | $23.17 | 2019 | |
| Upsher-Smith Laboratories LLC | $21.06 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.79 | 2020 | |
| Pfizer INC. | $19.12 | 2023 | |
| Aprecia Pharmaceuticals, LLC | $18.64 | 2021 | |
| Ucb, INC. | $17.67 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.82 | 2021 | |
| Eisai INC. | $15.09 | 2021 | |
| Genzyme Corporation | $14.68 | 2019 | |
| Celgene Corporation | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Beckhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.